Our growth strAtegy
Our future growth will be achieved by focusing on the following key areas:
Substantial increase in market access
We intend to drive revenue in the short term by focusing on distribution of Harpin aß by aligning with large distributors with broad market access. We plan to expand sales in broad acre crops where Harpin aß provides most benefits to farmers, including sugar cane, corn, soy, citrus, rice, almonds and grapes.
Launching peptide products from our PREtec platforms
In trials conducted by PHC and our partners in 2019, our lead peptide, PHC279, continued to provide impressive levels of disease control and improved yield in a variety of crops, including soybeans, corn, wheat and lettuces. Our application to sell PHC279 in Brazil for the treatment of Asian soybean rust was accepted by the relevant agencies, and we are anticipating a rapid approval process. We anticipate launches from 2021 onwards.
Building further the capability to deliver additional products from PREtec
Having now established pilot plant manufacturing capabilities at Penn State University’s CSL Behring Fermentation Facility, Plant Health Care can quickly scale up production of other PREtec peptides in our pipeline, including PHC949 and PHC414.
IP protection and ongoing innovation
The Group has an extensive library of PREtec peptides, which can be further expanded. The Group has now been granted the first patents for PREtec peptides by the US PTO; numerous filings are in the process of being reviewed around the world, as the Group builds its IP portfolio.
The Group is well positioned to consolidate the biologicals market due its capability to evaluate technologies and broad market access.